DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Revvity (RVTY) Launches New Molecular Testing for Newborns
by Zacks Equity Research
Revvity's (RVTY) EONIS Q System is set to transform SMA and SCID testing, advancing global healthcare for infants.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
3 Reasons to Retain Inspire Medical (INSP) Stock for Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.
Zacks.com featured highlights DaVita, Brinker International, CNA Financial and Integer Holdings
by Zacks Equity Research
DaVita, Brinker International, CNA Financial and Integer Holdings have been highlighted in this Screen of The Week article.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Patterson Companies (PDCO) Q2 Earnings Miss, EPS View Lowered
by Zacks Equity Research
Patterson Companies' (PDCO) second-quarter fiscal 2024 results reflect improvement in Dental Consumable sales, which were offset by lower Dental Equipment sales. Animal health sales improve.
4 Stocks Trading Near 52-Week High That Can Climb Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like DVA, EAT, CNA and ITGR that are seeing price strength have a high chance of carrying the momentum forward.
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Philips (PHG) Bolsters Diagnostic Imaging With New Launches
by Zacks Equity Research
Philips (PHG) unveils an array of AI-enabled innovations at RSNA23 to enhance diagnostic imaging capabilities across healthcare providers.
5 Finest PEG-Based Value Stocks to Buy Now
by Urmimala Biswas
Here are five stocks that match our screening criteria ¿¿¿ FOXA, DVA, LDOS, BLD and ITRI.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.
Haemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE), driven by a strategic focus on establishing leading positions in high-growth markets and raised guidance.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) strength in business raises optimism about the stock.
Haemonetics' (HAE) Plasma Growth, Innovation Aid Performance
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Philips (PHG) Adds BlueSeal to its Diagnostic Imaging Portfolio
by Zacks Equity Research
Philips (PHG) showcases BlueSeal MR Mobile to enhance diagnostic imaging capabilities across remote and rural communities.
Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.
Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes
by Zacks Equity Research
The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.
Insulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.